Key drivers of biomedical innovation in cancer drug discovery

Margit A Huber1,* & Norbert Kraut2,**

Discovery and translational research has led to the identification of a series of “cancer drivers”—genes that, when mutated or otherwise misregulated, can drive malignancy. An increasing number of drugs that directly target such drivers have demonstrated activity in clinical trials and are shaping a new landscape for molecularly targeted cancer therapies. Such therapies rely on molecular and genetic diagnostic tests to detect the presence of a biomarker that predicts response. Here, we highlight some of the key discoveries bringing precision oncology to cancer patients. Large-scale “omics” approaches as well as modern, hypothesis-driven science in both academic and industry settings have significantly contributed to the field. Based on these insights, we discuss current challenges and how to foster future biomedical innovation in cancer drug discovery and development.

Definition and translation of new therapeutic concepts

As exemplars of biomedical discoveries that have transformed the cancer treatment landscape, we will discuss recent therapeutic advances in malignant melanoma, non-small-cell lung cancer (NSCLC), acute myeloid leukemia (AML), and certain gynecological cancers.

In 2002, activating mutations in the gene encoding the serine/threonine kinase BRAF were identified by the Cancer Genome Project (Sanger Centre, UK) in a subset of human cancers, including about 50% of malignant melanomas (Davies et al, 2002). Less than 10 years later, the small-molecule kinase inhibitors vemurafenib and dabrafenib were approved for use in BRAF mutation-positive melanomas, as the front-runners in a competition between numerous companies engaged in cancer drug discovery (Bollag et al, 2012; Hauschild et al, 2012). As these compounds were made available to academic investigators (see Box 1), a broad range of studies emerged that investigated the mechanism of BRAF inhibition in BRAF-mutant tumors. Indeed, new insights, including on the activation of downstream pathway components such as MEK, have informed a recently approved targeted BRAF/MEK inhibitor combination of dabrafenib/trametinib (Flaherty et al, 2012).

In 2004, two Boston-based academic groups discovered EGFR mutations in NSCLC, one through a systematic kinome-directed sequencing approach (Paez et al, 2004), and the second thanks to a hypothesis-driven EGFR sequencing effort (Lynch et al, 2004). Both groups were able to link the presence of EGFR mutations with an outstanding sensitivity of mutation carriers to EGFR tyrosine kinase inhibitors (TKIs). This provided the basis for successful biomarker-guided clinical development of the two selective EGFR TKIs gefitinib and erlotinib, as well as the irreversible ErbB family blocker afatinib (Tartarone et al, 2014). About 60% of EGFR TKI-treated patients become resistant by developing the EGFR T790M mutation, and based on early clinical trials appear to respond well to next-generation mutant-selective/wild-type-sparing EGFR inhibitors such as AZD9291 and CO-1686 (Jänne et al, 2014; Sequist et al, 2014).

Using a functional genomics approach, a Japanese team in 2007 discovered a chromosomal translocation resulting in an aberrant fusion gene that encodes a constitutively

Box 1: Sharing of lead compounds with academia

Providing open access to “probe compounds” with attractive features such as potency, selectivity, cellular permeability, and ideally also suitable physicochemical properties to enable in vivo studies is an increasingly attractive concept for the pharmaceutical industry. Such probes are valued reagents in both fundamental and applied biological research and are key tools in drug discovery that allow preclinical target validation in both academic and industrial laboratories. Early sharing of lead compounds with academia may help the industry to prioritize between different therapeutic concepts, explore new disease links including patient selection strategies, inform effective combinatorial approaches, and gain insights into potential resistance mechanisms—highly valuable information that would fuel further translational research. Often, companies will not immediately publish the clinical candidate, but rather describe a closely related compound with very comparable features. Thus, sensitive structural data remain undisclosed, helping to mitigate perceived risks toward protection of intellectual property. For example, in the case of BRAF inhibitors, important new biological insight into the mechanisms of resistance and MAPK pathway activation was initially revealed with the BRAF inhibitor PLX4720 (Tsai et al, 2008), a compound closely related to PLX4032 (RG7204, vemurafenib) which was only later made available to the scientific community for preclinical studies, and subsequently became the first marketed BRAF inhibitor (Bollag et al, 2012).

1 Department of Dermatology and Allergic Diseases, Ulm University, Ulm, Germany
2 Oncology Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
*Corresponding author. Tel: +49 731 500 57647; E-mail: margit.huber@uniklinik-ulm.de
**Corresponding author. E-mail: norbert.kraut@boehringer-ingelheim.com
DOI 10.15252/emmm.201404596 | Published online 24 November 2014
Box 2: Predicting drug resistance to cancer drugs

Resistance to targeted therapies is commonly categorized as either primary (i.e. intrinsic) or secondary (i.e. acquired). Primary resistance indicates a direct lack of a treatment response, while acquired resistance is defined by disease progression following an initial response. Acquired resistance may be mediated by target modifications (e.g. secondary mutations or gene amplification of the target that will abrogate the inhibitory activity of the drug), “bypass signaling” resulting in reactivation of parallel and/or downstream signaling pathways, or histologic transformation. For EGFR TKIs, all of the above mechanisms of acquired resistance have been described clinically, including a secondary threonine-to-methionine substitution within the gatekeeper residue at position 790 (T790M), bypass signaling via amplification of the gene encoding the RTK MET to activate a parallel pathway, and phenotypic alterations either by an epithelial–mesenchymal transition, or even by a transformation from NSCLC to small-cell lung cancer (Sequist et al, 2011). Clinical studies of acquired resistance provide clear rationales on how to develop improved strategies to prevent or overcome resistance, guiding the development of next-generation inhibitors addressing secondary target mutations, or informing new combinations aimed at co-targeting of bypass tracks. Preclinical modeling of acquired resistance to targeted therapies also yields key insights into target modifications or bypass mechanisms providing the capacity to substitute for the driver oncogene and serves as a powerful starting point when searching for clinical resistance mechanisms. As a word of caution, only a subset of the preclinical resistance mechanisms are actually found in the clinical setting. For example, initial attempts to predict resistance mechanisms to BRAF inhibitors focused on generating mutations in the BRAF gatekeeper residue that is analogous to the clinically relevant residues in EGFR (T790M), BCR-ABL (T315I), and ALK (L1196M). Indeed, it turned out that although engineering of BRAF T529 gatekeeper mutations does confer vemurafenib resistance in vitro, these mutations have never been reported in tumor samples from BRAF inhibitor-resistant patients (Whittaker et al, 2010). Thus, in this case, the design of second-generation compounds based on the preclinical findings would have been premature.

A particularly good example of the contribution of modern molecular cell biology toward new treatment paradigms in AML is the field of cell cycle regulators. Here, the detailed understanding of how mitotic kinases such as polo-like kinase (Plk) 1 orchestrate mitosis, built over the years in basic academic research, inspired the industry to consider Plk1 inhibition as a potential therapeutic cancer target. Several small-molecule inhibitors have been developed that have enabled cell biologists to advance our understanding of Plk1 biology, and helped collaborating industry partners to develop Plk1 inhibition as an attractive therapeutic concept based on very efficient tumor cell killing and—in contrast to microtubule-targeting antimitic agents—specificity for proliferating versus non-proliferating cells (Steegmaier et al, 2007; Taylor & Peters, 2008). Importantly, recent clinical data in AML patients demonstrated that the Plk1 inhibitor volasertib combined with chemotherapy was associated with higher response rates and improved event-free survival than chemotherapy alone (Döhner et al, 2014).

Finally, turning to gynecological tumors, a breakthrough discovery by two groups in the UK showed that inhibitors of the DNA repair enzyme poly(ADP) ribose polymerase I (PARP1) preferentially killed cancer cells harboring defects in the homologous recombination (HR) repair tumor suppressors BRCA1 or BRCA2 (Bryant et al, 2005; Farmer et al, 2005). When HR is defective, alternative DNA repair mechanisms are utilized that then become dependent on PARP1. Key to the success of these studies have been the insights into DNA repair pathways made in basic academic research, as well as the availability of exquisite PARP inhibitor probe compounds

MYC (Zuber et al, 2011). Several companies have rapidly initiated discovery programs, and clinical trials probing the utility of BRD4 inhibitors for the treatment of AML are underway (Papavassiliou & Papavassiliou, 2014).

“Prioritizing the best possible targets requires collaborative efforts at research institutions and hospitals to establish improved preclinical models.”

active ALK kinase in a subset of NSCLCs (Soda et al, 2007). A mere 3 years later, dramatic clinical responses were reported in ALK-translocated NSCLC patients upon treatment with crizotinib (Kwak et al, 2010), followed by its FDA approval in 2011. Even though this drug was developed initially as a MET kinase inhibitor and only later recognized to potently block ALK activity, these remarkable timelines to successful clinical translation and approval were only made possible through close academic/industry collaborations. As is the case with other targeted therapies for oncogene-addicted tumors, resistance to crizotinib is inevitable and is observed in less than a year (Camidge et al, 2012). Importantly, ceritinib, a second-generation ALK TKI approved by the FDA earlier this year, appears to be effective against many of the known resistance mechanisms that arise in patients exposed to crizotinib (Shaw et al, 2014). Over the past several years, multiple molecular mechanisms of resistance to targeted therapies have been discovered, resulting in the emergence of several common themes (see Box 2).

Massive cancer genome surveys supported by public or private funding are now rapidly expanding the catalogue of genetic aberrations linked to a broad range of cancer types. The cancer genome landscape in AML (The Cancer Genome Atlas Research Network, 2013) has informed new precision oncology approaches beyond the use of kinase inhibitors. Thus, in addition to TKIs targeting FLT3, small-molecule inhibitors are being developed to address AML subtypes harboring oncogenic variants of the gene encoding isocitrate dehydrogenase (IDH) 2 (e.g. AG-221; Stein et al, 2014) and the mixed-lineage leukemia gene MLL1 (Dot1L inhibitor EPZ-5676; Daigle et al, 2013; ClinicalTrials.gov identifiers: NCT02141828, NCT01684150). In addition to the genome-based discoveries of “actionable” cancer genes, several examples of cancer-specific vulnerabilities are poised to yield new therapeutic advances and deserve discussion in this context. In AML, the gene encoding the bromodomain-containing protein 4 (BRD4) was identified by an epigenetically focused systematic in vivo RNAi screen at the Cold Spring Harbor Laboratory as highly essential for promoting proliferation and blocking differentiation. BRD-containing proteins function by binding acetylated lysines on histone residues and recruiting protein complexes, thereby regulating gene expression by modulating heterochromatin. When using a BRD4 inhibitory “probe compound” (for definition, see Box 1), discovered at the Dana-Farber Cancer Institute, anti-leukemic effects across genomic AML subtypes were precisely recapitulated and found to largely depend on blocking the oncogenic transcription factor
pioneered in industry. The discovery also delivered strong support to the concept of “synthetic lethality”, based on which mutations that are harmless on their own, when compounded can kill a cancer cell. Subsequent studies established that olaparib, a potent PARP inhibitor, yielded notable clinical activity in BRCA mutation carriers with breast and ovarian cancers (Fong et al., 2009), providing the basis for ongoing trials (Moore et al., 2014).

**Challenges in advancing new precision cancer therapies**

Recent surveys based on the sequencing of thousands of cancer genomes have yielded unprecedented insights into cancer genome landscapes (Vogelstein et al., 2013) and enabled the discovery of many new cancer genes, including several involved in cellular processes not previously thought to be causally linked to cancer (Garraway & Lander, 2013). In parallel, large-scale efforts, such as epigenomics, transcriptomics, proteomics, chemical genomics, and high-throughput functional screens have greatly increased our understanding of the underlying biology of cancer. While these transformative efforts continue to progress at a rapid pace, we perceive four key challenges going forward: how can we (i) prioritize the best possible targets; (ii) develop drugs against “undruggable” oncoproteins; (iii) restore tumor suppressor pathways; and (iv) identify highly effective drug combinations.

**Box 3: Partnerships between companies to test drug combinations**

The combination of investigational cancer therapies into a single development program offers an attractive approach for generating more effective cancer treatments. This strategy allows the targeting of multiple cancer pathways, or addressing more than one key node in a single pathway to prevent or overcome intrinsic or acquired resistance (see Box 2). A single biomedical company rarely has adequate resources or the success rate to effectively target all major oncogenic pathways, their key nodes, and respective resistance mechanisms. To move forward efficiently, companies should collaborate rather than compete to be successful in developing highly effective combination therapies. Fortunately, we see a clear trend that such collaborative efforts are in fact happening. This started in 2009, with competitors AstraZeneca and Merck forming a partnership to evaluate a combination of AstraZeneca’s MEK inhibitor and Merck’s AKT inhibitor in multiple early-stage clinical trials. Since then, other top tier pharmaceutical companies have agreed on strategic collaborations to share drugs and development costs. Notable examples include partnerships between Merck, KGAa and Sanofi on MEK and PISK inhibitor combinations, as well as Roche and BMS on investigating Roche’s vemurafenib in combination with BMS’s ipilimumab, an immune-checkpoint inhibitor targeting cytotoxic T-lymphocyte activator-4 (CTLA-4), in patients with BRAF-mutated malignant melanoma. In the area of immune-checkpoint modulators, companies are teaming up for combinations centered around inhibitors of programmed cell death-1 (PD-1) combinations with other immunotherapies or with targeted therapies (Sheridan, 2014). We see it as very important for the entire drug development community to fully embrace and foster collaboration models to best advance investigational combination therapies for the benefit of cancer patients.

“Drug companies are now increasingly teaming up to clinically test targeted pathway inhibitor combinations.”
test targeted pathway inhibitor combinations (Box 3).

A recipe for biomedical innovation

Collectively, innovation leading to effective new cancer therapies is driven by the convergence of basic scientific discoveries, rapidly improving genomic analysis technologies, and increasingly precise biomarker-guided development strategies. As illustrated, breakthrough innovation can equally well emerge from academia and industry and can arise both from “data first”, large-scale efforts and from creative, “hypothesis first”, modern molecular cell biology studies, often in a complementary and mutually beneficial manner.

“Major advances can only be made if academic and company investigators team up for equal partnerships.”

Biomedical scientists with a collaborative spirit, capable of networking across disciplines and beyond the classical academic and industry boundaries, and importantly those who are capable of integrating all relevant insights to address unmet medical needs, will be the true medical innovators. In our view, close academia/industry collaborations fuelled by open innovation are the most likely to succeed in generating and testing new therapeutic concepts and in translating the benefits to cancer patients. Thus, scientists and clinicians should be encouraged to engage in these interactions, despite some cultural barriers or the complications associated with managing intellectual property. To overcome these hurdles, truly innovative projects that—based on expertise and resources—would not be possible for either partner alone should be prioritized. Major advances can only be made if academic and company investigators team up for equal partnerships, take long-term views, share responsibilities and incentives, and build on their respective skill sets, with the ambition to succeed in a collective mission. Only with this integrated, dynamic, and open spirit can we jointly drive and accelerate the next stages of biomedical innovation to achieve meaningfully improved health outcomes for cancer patients.

Conflict of interest

MAH has previously been compensated as a consultant and speaker for Roche and as a speaker for MSD and Amgen. NK is an employee of Boehringer Ingelheim.

References

Bernards R (2014) Finding effective cancer therapies through loss of function genetic screens. Curr Opin Genet Dev 24: 23 – 29
Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P (2012) Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 11: 873 – 886
Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913 – 917
Camidge DR, Bang YJ, Kwak EL, laifrate AJ, Varella-Garcia M, Fox SB, Relyt CJ, Solomon B, Ou SH, Kim DW et al (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13: 1011 – 1019
Cancer Genome Atlas Research Network (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368: 2059 – 2074
Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, Scott JA, East A, Ali LD, Lizotte PH, Wong TC et al (2011) Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci USA 108: 12372 – 12377
Dagile SR, Olhava EJ, Therkelsen CA, Basavapathamani A, Jin L, Borajc-Sjodin PA, Allain Cj, Klaus CR, Raimando A, Scott MP et al (2013) Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122: 1017 – 1025
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffenden H, Garnett MJ, Bottomley W et al (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949 – 954
Döhner H, Lubbert M, Fiedler W, Fouillaud L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlupe P, Ottohn GM et al (2014) Randomized, phase 2 trial comparing low-dose cytarabine with or without vosarabine in AML patients not suitable for intensive induction therapy. Blood 124: 1426 – 1433
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917 – 921
Fellmann C, Hoffmann T, Sridhar V, Hopfgartner B, Muhar M, Roth M, Lai DY, Barbosa IA, Kwon JS, Guan Y et al (2013) An optimized microRNA backbone for effective single-copy RNAi. Cell Rep 5: 1704 – 1713
Flaherty KT, Infante JR, Daud A, Gonzalez R, Keeford RF, Soliman H, Mandard A, Schuchter L, Cebon J, Ibrahim N et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367: 1694 – 1703
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O’Connor MJ et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123 – 134
Garraway LA, Lander ES (2013) Lessons from the cancer genome. Cell 153: 17 – 37
Hauschild A, Grob J, Demidov LV, Jouary T, Gutzmier R, Millward M, Rutzowski P, Blank C, Miller WH Jr, Kaempgen E et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380: 358 – 365
Jänne PA, Ramalingam SS, Yang J, Atn MJ, Kim DW, Kim SW, Planchar D, Ohe Y, Felip E, Watkins C (2014) Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small-cell lung cancer (NSCLC). J Clin Oncol 32: Ss. (suppl; abstr 8009p)
Johnson DB, Smalley KS, Soliman JA (2014) Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. Clin Cancer Res 20: 4186 – 4192
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maig RS, Ou SH, Dezube BJ, Janne PA, Costa DB et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693 – 1703
Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsford AE, Jakubosky D, Genovese C, Muller FL, Jeong JH et al (2014) Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 18: 1503 – 1510
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129 – 2139
Moore KN, DiSilvestro P, Lowe ES, Garnett S, Pujade-Lauraine E (2014) SOLO1 and SOLO2: randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a
BRCA1/2 mutation (BRCAm). J Clin Oncol 32: 5 (suppl; abstr TP5616).
Mullard A (2011) Partnering between pharma peers on the rise. Nat Rev Drug Discov 10: 561 – 562.
Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM (2013) K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503: 548 – 551.
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497 – 1500.
Papadimitrakopoulou VA, Jaw-Tsai SS, Caunt L, Camidge DR, Varga A, Solomon BJ, Shaw AT, Gettinger S, Cosper AK, Digumarthy S, Turke AB, Fidias P, Bergethon K, Stein E, Tallman M, Pollyea DA, Flinn IW, Fathi AT, Stein E, Tallman M, Pollyea DA, Flinn IW, Fathi AT, Stone RM, Levine RL, Agresta S, Schenkein D, Yang H et al (2014) Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2-mutant positive advanced hematologic malignancies. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; 2014. Abstract nr CTI103.
Sequist LV, Waltman BA, Dias-Santagata D, Papadimitrakopoulou VA, J- Tsai SS, Caunt L et al (2014) First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). J Clin Oncol 32: 5s (suppl; abstr 8010).
Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T et al (2014) Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370: 1189 – 1197.
Sheridan C (2014) Immune-checkpoint inhibitors march on, now in combinations. Nat Biotechnol 32: 297 – 299.
Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561 – 566.
Steegmaier M, Hoffmann M, Baum A, Lénárt P, Scharfetter-Kochanek K, Peter M, Petronczki M, Krssák M, Gürtler U, Garin-Chesa P, Lieb S, Quant J et al (2007) BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17: 316 – 322.
Stein E, Tallman M, Pollyea DA, Flinn IW, Fathi AT, Stone RM, Levine RL, Agresta S, Schenkein D, Yang H et al (2014) Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2-mutant positive advanced hematologic malignancies. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; 2014. Abstract nr CTI103.
Tartarone A, Lerose R, Lazzeri C, Gregoric V, Aleta M (2014) Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations? Med Oncol 31: 78.
Taylor S, Peters JM (2008) Polo and Aurora kinases: lessons derived from chemical biology. Curr Opin Cell Biol 20: 77 – 84.
Toniatti C, Jones P, Graham H, Pagliara B, Draetta G (2014) Oncology drug discovery: planning a turnaround. Cancer Discov 4: 397 – 404.
Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK et al (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105: 3041 – 3046.
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013) Cancer genome landscapes. Science 339: 1546 – 1558.
Whittaker S, Kirk R, Hayward R, Zambon A, Viros A, Cantarino N, Affolter A, Noury A, Niculescu-Duvaz D, Springer C et al (2010) Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci Transl Med 2: 35ra41.
Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M et al (2011) RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524 – 528.

License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.